Dear colleagues,

Happy new year full of happiness, peace, and success!

In the current issue, the editorial by Conti, et al. provides an updated overview of the emerging therapies for inflammatory bowel diseases and highlights the need of personalized medicine. Moreover, this issue includes five review articles. The first review, by Amptoulach S. summarizes the latest data regarding the systematic treatment of metastatic esophagogastric adenocarcinoma (EGAC) and esophageal squamous cell carcinoma (ESCC), discusses the updates in the molecular targeted agents and summarizes significant locally advanced and metastatic EGAC- and ESCC-related clinical trials. The review by Travlos et al. provides the current knowledge concerning the use of new oral anticoagulants in the prevention of thromboembolic events in patients with atrial fibrillation. The review by Balta L. describes the advances in the classification of patients with chronic kidney disease (CKD) and demonstrates the prerequisites for achieving the optimal outcomes for CKD patients. The review, by Moulias et al. presents data on the high sensitivity cardiac troponin assays diagnostic utility and summarizes primary principles for their appropriate, safe and effective use in clinical practice. Lastly, the review by Lagadinou et al. provides a general overview of the diagnostic approach of fever in people living in rural areas, highlighting the need of health workers' proper training since early diagnosis and proper treatment are critical.

Lastly, it is with great pleasure that I introduce our new Editorial Board members for the years 2023-2024. Thank you all for participating!

C. Triantos

Associate Professor in Internal Medicine and Gastroenterology Faculty of Medicine, School of Health Sciences, University of Patras Editor-in-Chief of the journal "ACHAIKI IATRIKI"